Sørensen Per Soelberg, Sellebjerg Finn
Rigshospitalet, Dansk Multipel Sclerose Center, Neurologisk Afdeling 2082, København Ø.
Ugeskr Laeger. 2008 Jun 9;170(24):2156-9.
In 1996 interferon (IFN)beta was the first biopharmaceutical product to be approved for the treatment of relapsing-remitting multiple sclerosis (MS). In 2006 the more potent monoclonal antibody natalizumab was approved. Presently, a number of monoclonal antibodies are being studied, including alemtuzumab, daclizumab and rituximab, which have all shown promising results. However, the monoclonal antibodies generally have a less favourable safety profile and are more expensive than the currently used first-line therapies, IFNb and glatiramer acetate.
1996年，干扰素β成为首个被批准用于治疗复发缓解型多发性硬化症（MS）的生物制药产品。2006年，效力更强的单克隆抗体那他珠单抗获得批准。目前，多种单克隆抗体正在研究中，包括阿仑单抗、达利珠单抗和利妥昔单抗，它们均已显示出有前景的结果。然而，单克隆抗体总体上安全性较差，且比目前使用的一线疗法（干扰素β和醋酸格拉替雷）更昂贵。
